Clinical Report: Collagenase Effective for Recurrent Dupuytren
Overview
Collagenase clostridium histolyticum (CCH) injections provide a safe and effective nonsurgical treatment for recurrent Dupuytren contracture after prior surgery. The study demonstrated significant improvements in joint extension and a favorable safety profile.
Background
Dupuytren contracture is a fibroproliferative disorder that leads to progressive finger flexion contractures, significantly impairing hand function. Surgical options often result in recurrence, which can complicate subsequent interventions due to scar tissue and altered anatomy. Exploring nonsurgical alternatives like CCH is crucial for improving patient outcomes.
Data Highlights
| Measure | Baseline Contracture (°) | Mean Improvement (°) | Clinical Success (%) |
|---|---|---|---|
| Overall | 52 | 38 | 58 |
| MP Joints | - | 36 | 75 |
| PIP Joints | - | 41 | 43 |
Key Findings
- CCH injections were administered to 101 patients with recurrent Dupuytren contracture.
- Mean contracture improved by 43° at the first evaluation and remained improved by 38° at the final evaluation.
- Clinical success was achieved in 65% of treated joints at the first evaluation and 58% at the last evaluation.
- Adverse events occurred in 36% of patients, with skin tears being the most common complication.
- Outcomes were more favorable in metacarpophalangeal joints compared to proximal interphalangeal joints.
Clinical Implications
CCH offers a viable nonsurgical option for patients with recurrent Dupuytren contracture, potentially reducing the need for repeat surgeries that carry higher complication risks. Clinicians should consider CCH as part of shared decision-making for managing recurrent cases.
Conclusion
The findings suggest that CCH is an effective and well-tolerated treatment for recurrent Dupuytren contracture, with outcomes comparable to those in patients treated without prior surgery.
References
- Aguado-Maestro I., Archives of Orthopaedic and Trauma Surgery, 2024 -- Recurrence Rates in Dupuytren's Disease Following Treatment with Clostridium Histolyticum Collagenase
- Aguado-Maestro I., Archives of Orthopaedic and Trauma Surgery, 2024 -- Recurrence of Dupuytren's Disease After Treatment with Clostridium Histolyticum Collagenase
- Austrian Registry Study, Archives of Orthopaedic and Trauma Surgery, 2019 -- Use of Clostridium histolyticum Collagenase for Managing Dupuytren’s Disease
- ACOEM, 2025 -- Hand, Wrist, and Forearm Disorders Guideline
- Hurst L.C., The New England Journal of Medicine, 2009 -- Treatment of Dupuytren Contracture Recurrence After Surgery With Collagenase Clostridium Histolyticum
- Comparison of Polytetrafluoroethylene (PTFE) Sutures with Fiberwire and Polypropylene for Flexor Tendon Repair
- Dupuytren's Disease Overview
- ACOEM Hand, Wrist, and Forearm Disorders
- Treatment of Dupuytren Contracture Recurrence After Surgery With Collagenase Clostridium Histolyticum: A Retrospective Multicenter Series - ScienceDirect
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
